Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs
Keyword(s):
Nearly 90% of the diabetic patients are suffering of type 2 diabetes while approximately 60-65% of patients with type 2 diabetes are treated with oral antidiabetic drugs. In the last couple of years a new treatment option, namely incretin-based therapy, became available. The dipeptidyl-peptidase-4-inhibitors (gliptins) are designated as incretin enhancers. Using gliptins, sustained glycemic control can be achieved without gaining weight and increasing the risk of hypoglycemia. All gliptins (sitagliptin, vildagliptin, saxagliptin, linagliptin) can be used as tablets without a need for dose titration. For treating patients with type 2 diabetes, gliptins can primarily be used in combination with metformin. Orv. Hetil., 2011, 152, 1471–1476.
2017 ◽
Vol 83
(7)
◽
pp. 1556-1570
◽
2021 ◽
Vol 2021
◽
pp. 1-8
2021 ◽
pp. 53-59
2015 ◽
Vol 22
(13)
◽
pp. 1573-1581
◽
2020 ◽
Vol 79
(Suppl 1)
◽
pp. 1250.2-1251